Anesthesia for Electroconvulsive Therapy Time for a Review?
[1] Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord 2001;16:197e201. [2] Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992;55:181e4. [3] Welter ML, SchupbachM, Czernecki V, et al. Optimal target localization for subthalamic stimulation in patientswithParkinson disease. Neurology 2014;82:1352e61. [4] Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT PD) Mov Disord 1999;14:572e84. [5] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta analysis protocols (PRISMA P) 2015 statement. Syst Rev 2015;4:1. [6] Katayama Y, Kasai M, Oshima H, et al. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa intolerant patients. J Neurosurg 2001;95:213e21. [7] Martinez Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015;30:510e6. [8] Charles PD, Van Blercom N, Krack P, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002;59:932e4. [9] Obeso JA, Rodriguez Oroz MC, Benitez Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's Disease. Mov Disord 2008;23:S548e59. [10] Tai CH, Pan MK, Lin JJ, Huang CS, Yang CY, Kuo CC. Subthalamic discharges as a causal determinant of parkinsonian motor deficits. Ann Neurol 2012;72:464e76.
Brain Stimulation